AI Terminal
BB Biotech AG
AGM Information • Mar 20, 2025
833_rns_2025-03-20_b64477ec-4adf-4449-9057-1f7aab94182b.html
AGM Information
Open in ViewerOpens in native device viewer
News Details
Corporate | 19 March 2025 17:45
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
BB BIOTECH AG / Key word(s): AGM/EGM/Dividend
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
19.03.2025 / 17:45 CET/CEST
The issuer is solely responsible for the content of this announcement.
Media release of March 19, 2025
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
All proposals of BB Biotech AG’s Board of Directors were approved by BB Biotech AG’s shareholders at its Annual General Meeting held today.
Shareholders voted in favor of the proposal to pay out a dividend of CHF 1.80 gross per share. Payment will be made on March 25, 2025, the record date is March 24, 2025 and the ex-dividend date is March 21, 2025.
Shareholders re-elected the previous board members Dr. Thomas von Planta (Chairman), Dr. Clive Meanwell, Laura Hamill, Dr. Pearl Huang, Prof. Dr. Mads Krogsgaard Thomsen and Camilla Soenderby for another one-year term of office.
For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00
Head Investment Management Team BB Biotech
Dr. Christian Koch
Investor Relations
Claude Mikkelsen, [email protected]
Media Relations
Tanja Chicherio, [email protected]
Company profile
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.
19.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | BB BIOTECH AG |
| Schwertstrasse 6 | |
| 8200 Schaffhausen | |
| Switzerland | |
| Phone: | +41 52 624 08 45 |
| E-mail: | [email protected] |
| Internet: | www.bbbiotech.ch |
| ISIN: | CH0038389992 |
| WKN: | A0NFN3 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Mailand, SIX |
| EQS News ID: | 2103154 |
| End of News | EQS News Service |
2103154 19.03.2025 CET/CEST